-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target

Benzinga·09/24/2026 13:55:24
语音播报
Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.